These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33888142)

  • 21. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
    Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
    J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer.
    Huang Z; Yan Y; Wang T; Wang Z; Cai J; Cao X; Yang C; Zhang F; Wu G; Shen B
    J Transl Med; 2022 Jul; 20(1):315. PubMed ID: 35836227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer.
    Du Y; Liu Y; Cao J; Jiang X; Wang Y; Yu J; Wang B; Wang X; Xue B
    Front Immunol; 2023; 14():1113756. PubMed ID: 37153545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of SNCA and its methylation in bladder cancer.
    Wu Z; Xia C; Zhang C; Yang D; Ma K
    BMC Cancer; 2022 Mar; 22(1):330. PubMed ID: 35346107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
    Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
    Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
    [No Abstract]   [Full Text] [Related]  

  • 27. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
    Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
    Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and Prognostic Values of the Roof Plate-Specific Spondin Family in Bladder Cancer.
    Gao L; Meng J; Zhang M; Fan S; Gao S; Wang X; Liang C
    DNA Cell Biol; 2020 Jun; 39(6):1072-1089. PubMed ID: 32352838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database.
    Hu J; Wang L; Li L; Wang Y; Bi J
    BMC Cancer; 2022 Nov; 22(1):1158. PubMed ID: 36357874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
    Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
    Front Immunol; 2021; 12():791924. PubMed ID: 34975891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HYAL3 as a potential novel marker of BLCA patient prognosis.
    Liu JP; Fang YT; Jiang YF; Lin H
    BMC Genom Data; 2022 Aug; 23(1):63. PubMed ID: 35945500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
    Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
    BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EIF4A3 serves as a prognostic and immunosuppressive microenvironment factor and inhibits cell apoptosis in bladder cancer.
    Hu B; Chen R; Jiang M; Xiong S; Liu X; Fu B
    PeerJ; 2023; 11():e15309. PubMed ID: 37180585
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Zhao X; Hu J; Li J; Gu L; Chen J; Othmane B; Gong G; Yuan J; Deng H
    Dis Markers; 2022; 2022():7147279. PubMed ID: 35909893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive analysis of PRPF19 immune infiltrates, DNA methylation, senescence-associated secretory phenotype and ceRNA network in bladder cancer.
    Wang Y; Wang J; He J; Ji B; Pang Z; Wang J; Liu Y; Ren M
    Front Immunol; 2023; 14():1289198. PubMed ID: 38022515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EPHA3 Could Be a Novel Prognosis Biomarker and Correlates with Immune Infiltrates in Bladder Cancer.
    Liu J; Zhou Z; Jiang Y; Lin Y; Yang Y; Tian C; Liu J; Lin H; Huang B
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
    Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
    Front Immunol; 2022; 13():916800. PubMed ID: 35860239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.
    Pan JH; Zhou H; Cooper L; Huang JL; Zhu SB; Zhao XX; Ding H; Pan YL; Rong L
    Front Immunol; 2019; 10():6. PubMed ID: 30761122
    [No Abstract]   [Full Text] [Related]  

  • 40. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
    Bai Y; Zhang Q; Liu F; Quan J
    Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.